TENAX THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TENAX THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | Mar 16, 2017 |
| FY2016 | Dec 31, 2015 | $0 | Mar 16, 2017 |
| FY2015 | Apr 30, 2015 | $49.3K | Jul 14, 2015 |
| FY2014 | Apr 30, 2014 | $158.9K | Jul 29, 2014 |
| FY2013 | Apr 30, 2013 | $1.19M | Jun 26, 2013 |
| FY2012 | Apr 30, 2012 | $363.8K | Jul 25, 2012 |
| FY2012 | Apr 30, 2011 | $103.2K | Jul 25, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2024 | $0 | Mar 25, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | Mar 16, 2017 |
| FY2016 | Dec 31, 2015 | $0 | Mar 16, 2017 |
| FY2015 | Apr 30, 2015 | $0 | Jul 14, 2015 |
| FY2014 | Apr 30, 2014 | ($104.1K) | Jul 29, 2014 |
| FY2013 | Apr 30, 2013 | $49.6K | Jun 26, 2013 |
| FY2012 | Apr 30, 2012 | $49.3K | Jul 25, 2012 |
| FY2012 | Apr 30, 2011 | $103.2K | Jul 25, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.60M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($17.60M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($7.71M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $11.05M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($32.47M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($9.85M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($8.39M) | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | ($14.14M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($8.84M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($43.92M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($56.39M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($19.49M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($8.23M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $11.05M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($32.73M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $9.87M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($8.56M) | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | ($6.89M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($9.21M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($52.65M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.67M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $12.71M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $3.23M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $5.38M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $25.15M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.56M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $3.47M | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.24M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.53M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $13.14M | Apr 2, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $7.58M | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | $5.31M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.08M | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | $5.65M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $5.68M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.25M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $3.94M | Mar 16, 2017 |
| FY2016 | Apr 30, 2015 | $7.17M | Mar 16, 2017 |
| FY2016 | Apr 30, 2014 | $13.77M | Mar 16, 2017 |
| FY2014 | Apr 30, 2013 | $3.68M | Jul 29, 2014 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.80M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($14.81M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($5.90M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($11.39M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($10.86M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($9.27M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($7.56M) | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | ($5.50M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($12.14M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($15.87M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.3K | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $5.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.5K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $3.6K | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | $7.6K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $4.5K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.9K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $16.7K | Mar 16, 2017 |
| FY2016 | Apr 30, 2015 | $4.2K | Mar 16, 2017 |
| FY2016 | Apr 30, 2014 | $9.8K | Mar 16, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.23M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $96.69M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $11.69M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $3.40M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.99M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $6.87M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $6.37M | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | $13.34M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $9.89M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $23.34M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.16M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $4.69M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $3.59M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.91M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.75M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.24M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $2.59M | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.57M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.01M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.20M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.07M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $91.99M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $8.10M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $1.49M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | $4.24M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $4.63M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $3.77M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $11.77M | Apr 16, 2021 |
| FY2019 | Dec 31, 2017 | $8.88M | Mar 30, 2020 |
| FY2017 | Dec 31, 2016 | $17.14M | Apr 2, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | Mar 16, 2017 |
| FY2016 | Dec 31, 2015 | $11.27M | Mar 16, 2017 |
| FY2015 | Apr 30, 2015 | $11.27M | Jul 14, 2015 |
| FY2014 | Apr 30, 2014 | $11.27M | Jul 29, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($367.45M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($314.86M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($297.25M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($289.54M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($278.49M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($246.02M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($236.17M) | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | ($227.80M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($213.50M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($204.66M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.60M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $94.90M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $9.80M | Mar 25, 2025 |
| FY2022 | Dec 31, 2022 | $2.12M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $5.58M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $6.25M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $4.91M | Apr 16, 2021 |
| FY2020 | Dec 31, 2018 | $12.37M | Apr 16, 2021 |
| FY2019 | Dec 31, 2017 | $1.60M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $10.00M | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (31) | Mar 25, 2025 |
| FY2014 | Apr 30, 2014 | (2) | Jul 29, 2014 |
| FY2014 | Apr 30, 2013 | (6) | Jul 29, 2014 |
| FY2013 | Apr 30, 2012 | (12) | Jun 26, 2013 |
| FY2012 | Apr 30, 2011 | 0 | Jul 25, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (31) | Mar 25, 2025 |
| FY2014 | Apr 30, 2014 | (2) | Jul 29, 2014 |
| FY2014 | Apr 30, 2013 | (6) | Jul 29, 2014 |
| FY2013 | Apr 30, 2012 | (14) | Jun 26, 2013 |
| FY2012 | Apr 30, 2011 | 0 | Jul 25, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.31M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 3.42M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 298,281 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 28,648 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 1.26M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 12.62M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 6.74M | Apr 16, 2021 |
| FY2019 | Dec 31, 2018 | 3.79M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 1.41M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 1.41M | Apr 2, 2018 |